Xeris Pharmaceuticals Inc. (XERS) Tops Q4 EPS by 3c, provides guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.03), $0.03 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $60.1 million versus the consensus estimate of $55.99 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2025 revenue of $255-275 million, versus the consensus of $239.8 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• HeartSciences (HSCS) files $200M mixed shelf
• ShinyHunters hackers say they stole psychiatric and medical records of DBI staff - Reuters